Use of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. Background: TN breast cancers are associated with young onset, high-risk pathology, distant metastases and poor prognosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results